FIELD: medicine.
SUBSTANCE: what is offered is using cyproheptadine as an agent preventing developing disorders in pulmonary tissue and blood system caused by the introduction of cytostatics. It is shown that cyproheptadine prevents alveoli infiltration, oedema of interalveoral septum, connective tissue development in lungs with reducing blood lymphocyte count and peripheral blood and bone marrow neutrophilic granulocyte count.
EFFECT: invention may be used for pharmacological correction of pulmonary fibrosis and blood system disorders developing with prescribing anticancer preparations.
1 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2012 |
|
RU2479312C1 |
PREPARATION PREVENTING DEVELOPMENT OF ABNORMALITIES IN LUNG TISSUE UNDER CYTOSTATIC IMPACT | 2011 |
|
RU2455991C1 |
AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2013 |
|
RU2530651C1 |
METHOD FOR IMPROVING THERAPEUTIC EFFECTIVENESS IN LUNG TISSUE DISORDERS AFTER ACTION OF CYTOSTATICS | 2012 |
|
RU2497523C1 |
METHOD OF TREATING PULMONARY FIBROSIS | 2012 |
|
RU2494470C1 |
AGENT FOR CORRECTING PULMONARY TISSUE DISORDERS UNDER CYTOSTATIC EXPOSURE | 2013 |
|
RU2554776C1 |
PREPARATION PREVENTING DEVELOPMENT OF DEPRESSION OF ERITHROID HEMATOPOIESIS SHOOT WITH INTRODUCTION OF CYTOSTATIC | 2007 |
|
RU2354376C1 |
DRUG POSSESSING REGENERATIVE ACTIVITY | 2011 |
|
RU2480236C1 |
MEANS FOR PNEUMOFIBROSIS PREVENTION AND TREATMENT AND METHOD FOR ITS PRODUCTION | 2016 |
|
RU2646810C1 |
TREATMENT METHOD FOR HEMATOPOIETIC ERYTHROID LINEAGE DEPRESSION IN CYTOSTATIC MYELOSUPRESSION | 2008 |
|
RU2364398C1 |
Authors
Dates
2012-10-27—Published
2011-06-08—Filed